Retinal Consultants Medical Group | Modesto, CA

Research site

(Unclaimed)

Location

4712 Stoddard Road Suite 180, Modesto, California, United States of America

Site insights

Top conditions

Top treatments

Faricimab

Aflibercept

EYE103

BI 1584862

RO7446603

Pegcetacoplan

Tarcocimab

RO7497372

EYP-1901

BI 771716

Parent organization

This site is a part of Retinal Consultants Medical Group

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

11 of 14 total trials

A 2-part Study Consisting of a Multiple Ascending Dose Safety Study in Participants With Macular Edema Following Branch Retinal Vein Occlusion and a Dose-finding Safety and Preliminary Efficacy Study in Participants With Either Diabetic Macular Edema or Neovascular Age-related Macular Degeneration

EYE-TIE-201 is a 2-part study to investigate the safety and effectiveness of a new drug being developed called EYE201.All participants in the study w...

Enrolling

BRVO - Branch Retinal Vein Occlusion

Diabetic Macular Edema (DME)

Drug: EYE201

A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56

This is a phase 3 randomized, double -masked study comparing the efficacy of EYP-1901 against Aflibercept.

Enrolling

Wet Age Related Macular Degeneration

wAMD

Drug: Aflibercept (2.0 mg)

Drug: EYP-1901

Locations recently updated

A Study to Evaluate the Efficacy and Safety of 2 Doses of EYE103 Compared With Ranibizumab (0.5 mg) in Participants With DME (BRUNELLO)

EYE-RES-102 is a randomized, double masked pivotal study to evaluate the efficacy and safety of 2 dose levels of EYE103 in comparison with the active...

Enrolling

Diabetic Macular Edema (DME)

Drug: EYE103

Drug: Ranibizumab

A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) - DAYBREAK

A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants with Neovascular (...

Enrolling

Wet Age-related Macular Degeneration

Drug: Tarcocimab tedromer

Drug: Aflibercept

A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer Compared With Sham Treatment in Participants With Diabetic Retinopathy (DR) (GLOW2)

This study will demonstrate that tarcocimab 5 mg is superior to sham treatment in participants with DR.

Active, not recruiting

Diabetic Retinopathy

Drug: Tarcocimab

Other: Sham injection

Locations recently updated

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7446603 Administered Alone or in Combination With Aflibercept or Faricimab in Participants With Diabetic Macular Edema (THAMES)

This study aims to evaluate the ocular and systemic safety, tolerability and efficacy of RO7446603 in participants with diabetic macular edema (DME)....

Enrolling

Diabetic Macular Edema

Drug: Faricimab

Drug: Aflibercept

A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7497372 in Participants With Diabetic Macular Edema (DME) (Pregonda)

This study will assess the safety and tolerability of RO7497372 in participants with DME. The study consists of 2 parts. Part 1 will test multiple-as...

Enrolling

Diabetic Macular Edema

Drug: RO7497372

A Study to Test Different Doses of BI 1584862 in People With a Distinct Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy

This study is open to adults aged 55 years and older with geographic atrophy that was diagnosed by imaging of the retina. The purpose of this study i...

Enrolling

Geographic Atrophy

Drug: BI 1584862

Drug: Placebo-matching BI 1584862

A Study to Test Whether BI 771716 Helps People With an Advanced Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy (VERDANT)

This study is open to people 50 years or older with an eye condition called geographic atrophy. The purpose of this study is to compare a medicine ca...

Enrolling

Macular Degeneration, Age-related

Geographic Atrophy

Drug: Pegcetacoplan

Drug: Sham comparator to BI 771716

Safety and Efficacy of Faricimab in Patients With NPDR (MAGIC)

The purpose of this Phase 2 study is comprised of two groups to evaluate the safety, tolerability, and efficacy of faricimab in patients with Non-Pro...

Active, not recruiting

Non-Proliferative Diabetic Retinopathy

Drug: Faricimab